CA2235371A1 - Formes polymorphes d'un agent de secretion d'hormone de croissance - Google Patents

Formes polymorphes d'un agent de secretion d'hormone de croissance Download PDF

Info

Publication number
CA2235371A1
CA2235371A1 CA002235371A CA2235371A CA2235371A1 CA 2235371 A1 CA2235371 A1 CA 2235371A1 CA 002235371 A CA002235371 A CA 002235371A CA 2235371 A CA2235371 A CA 2235371A CA 2235371 A1 CA2235371 A1 CA 2235371A1
Authority
CA
Canada
Prior art keywords
growth hormone
polymorphic form
amino
carbonyl
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002235371A
Other languages
English (en)
Inventor
Jerome P. Draper
David C. Dubost
Michael J. Kaufman
James A. Mccauley
Jennifer L. Vandrilla
Richard J. Varsolona
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9603361.8A external-priority patent/GB9603361D0/en
Application filed by Individual filed Critical Individual
Publication of CA2235371A1 publication Critical patent/CA2235371A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Fodder In General (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Cette invention se rapporte à des formes polymorphes du composé N-[1(R)-[(1,2-dihydro-1-méthanesulfonylspiro[3H-indole-3,4'-piperdin]-1'-yl)carbonyl]-2-(phénylméthyloxy)éthyl]-2-amino-2-méthylpropanamide méthanesulfonate qui est un agent de sécrétion d'hormone de croissance s'avérant utile d'une part pour favoriser la croissance des animaux destinés à l'alimentation, ce qui permet d'optimiser la production de produits carnés comestibles, et d'autre part pour traiter, chez des sujets humains, des troubles physiologiques ou médicaux caractérisés par une carence en sécrétion d'hormone de croissance de même que des états pathologiques qui sont améliorés par les effets anabolisants de l'hormone de croissance. Les formes polymorphes instantanées possèdent des avantages sur les autres formes connues de N-[1(R)-[(1,2-dihydro-1-méthanesulfonylspiro[3H-indole-3,4'-piperdin]-1'-yl)carbonyl]-2-(phénylméthyloxy)éthyl]-2-amino-2-méthylpropanamide méthanesulfonate en ce qui concerne la stabilité thermodynamique et l'aptitude à l'incorporation à des formulations pharmaceutiques. La présente invention se rapporte également à des procédés de préparation de ces formes polymorphes, à des formulations pharmaceutiques contenant lesdites formes polymorphes en tant qu'ingrédients actifs ainsi qu'à l'utilisation des formes polymorphes du composé et de leurs formulations pour le traitement de certains troubles.
CA002235371A 1995-10-27 1996-10-23 Formes polymorphes d'un agent de secretion d'hormone de croissance Abandoned CA2235371A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US590095P 1995-10-27 1995-10-27
US60/005,900 1995-10-27
GBGB9603361.8A GB9603361D0 (en) 1996-02-16 1996-02-16 Polymorphic forms of a growth hormone secretagogue
GB9603361.8 1996-02-16
PCT/US1996/016955 WO1997015574A1 (fr) 1995-10-27 1996-10-23 Formes polymorphes d'un agent de secretion d'hormone de croissance

Publications (1)

Publication Number Publication Date
CA2235371A1 true CA2235371A1 (fr) 1997-05-01

Family

ID=26308741

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002235371A Abandoned CA2235371A1 (fr) 1995-10-27 1996-10-23 Formes polymorphes d'un agent de secretion d'hormone de croissance

Country Status (22)

Country Link
EP (1) EP1019402A1 (fr)
JP (1) JP3204266B2 (fr)
KR (1) KR19990067098A (fr)
CN (1) CN1067687C (fr)
AU (1) AU707946B2 (fr)
BG (1) BG102476A (fr)
BR (1) BR9611229A (fr)
CA (1) CA2235371A1 (fr)
CO (1) CO4770956A1 (fr)
CZ (1) CZ128098A3 (fr)
EA (1) EA000528B1 (fr)
EE (1) EE9800147A (fr)
HK (1) HK1017894A1 (fr)
HU (1) HUP9902208A3 (fr)
IS (1) IS4721A (fr)
NO (1) NO310556B1 (fr)
NZ (1) NZ321370A (fr)
PL (1) PL327511A1 (fr)
SK (1) SK51398A3 (fr)
TR (1) TR199800726T2 (fr)
WO (1) WO1997015574A1 (fr)
YU (1) YU56696A (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046333A (en) * 1996-10-25 2000-04-04 Merck & Co., Inc. Convergent process for the preparation of a growth hormone secretagogue
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
WO2017075535A1 (fr) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Méthodes de traitement de troubles neurodégénératifs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ151495A3 (en) * 1992-12-11 1995-12-13 Merck & Co Inc Spiropiperidine derivatives, process of their preparation and a pharmaceutical composition containing thereof

Also Published As

Publication number Publication date
CZ128098A3 (cs) 1998-09-16
EA000528B1 (ru) 1999-10-28
JP3204266B2 (ja) 2001-09-04
SK51398A3 (en) 1998-12-02
JPH10512295A (ja) 1998-11-24
CO4770956A1 (es) 1999-04-30
EP1019402A1 (fr) 2000-07-19
YU56696A (sh) 1999-09-27
CN1205703A (zh) 1999-01-20
NO981867D0 (no) 1998-04-24
NO310556B1 (no) 2001-07-23
MX9803351A (es) 1998-09-30
AU7468696A (en) 1997-05-15
CN1067687C (zh) 2001-06-27
WO1997015574A1 (fr) 1997-05-01
EE9800147A (et) 1998-12-15
KR19990067098A (ko) 1999-08-16
NZ321370A (en) 1999-11-29
EA199800335A1 (ru) 1998-12-24
BG102476A (en) 1999-04-30
BR9611229A (pt) 1999-05-25
HUP9902208A3 (en) 2001-05-28
NO981867L (no) 1998-06-29
AU707946B2 (en) 1999-07-22
PL327511A1 (en) 1998-12-21
HK1017894A1 (en) 1999-12-03
TR199800726T2 (xx) 1998-08-21
HUP9902208A2 (hu) 1999-10-28
IS4721A (is) 1998-04-21

Similar Documents

Publication Publication Date Title
US6123964A (en) Wet granulation formulation of a growth hormone secretagogue
US5767124A (en) Polymorphic forms of a growth hormone secretagogue
US5777112A (en) Piperazine compounds promote release of growth hormone
US5783582A (en) Piperidines and hexahydro-1H-azepines spiro substituted at the 4-position promote release of growth hormone
DE60112753T2 (de) Verbindungen zur stimulation der sekretion von wachstumshormonen
WO1998010653A1 (fr) Piperidines, pyrrolidines et hexahydro-1h-azepines favorisant la secretion d'hormone de croissance
AU2001266066A1 (en) Growth hormone secretagogues
JPH10506914A (ja) 4−複素環式ピペリジンは成長ホルモンの放出を促進する
AU7522896A (en) Wet granulation formulation of a growth hormone secretagogue
WO1997036873A1 (fr) Piperidines, pyrrolidines et hexahydro-1h-azepines declenchant la liberation de l'hormone de croissance
KR100699404B1 (ko) 성장 호르몬 분비촉진제로서의 신규 아미드 유도체
GB2297972A (en) Camphor compounds promote release of growth hormone
US6420376B1 (en) Amido spiropiperidines promote the release of growth hormone
AU707946B2 (en) Polymorphic forms of a growth hormone secretagogue
US7022677B1 (en) Amide derivatives as growth hormone secretagogues
MXPA98003351A (en) ot. POLYMORPHIC FORMS OF A GROWTH HORMONE SECRETAGOGUE
BRPI9611229B1 (pt) Polymorphic form of the compound of N- [1 (R) - [(1,2-dihydro-1-methanesulfonyl-spiro [3 H -indol-3,4'-piperdin] -1'-yl) carbonyl] -2- - (phenylmethyl oxy) ethyl] -2-amino-2-methylpropanamide and pharmaceutical composition
CZ20003152A3 (cs) Soli N-methyi-N-((lR)-l-(N-methyl-N-((lR)-l- (methylkarbamoyl)-2-fenylethyl)karbamoyl)-2 (2-naftyl)ethyl)amidu (2E)-5-amino-5-methylhex- 2-enové kyseliny
UA61056C2 (en) Componuds with properties of growth hormone release, as pharmaceutical composition, a method for stimulating the growth hormone release from the pituitary and a method for increasing animal growth rate

Legal Events

Date Code Title Description
FZDE Discontinued